MedTrace Logo

The Effect of Ginkgolide on Clinical Improvement of Patients With Acute Ischemic Stroke

NCT05663307 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-12-29

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety and effectivity of Ginkgo diterpene lactone meglumine injection tn the treatment of acute ischemic stroke

Conditions

  • Ischemic Stroke, Acute

Interventions

DRUG

Ginkgo diterpene lactone meglumine injection

Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.

DRUG

Ginkgo diterpene lactone meglumine injection simulation

Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.

DRUG

Aspirin

plus aspirin at a dose of 100 mg per day for 90 days.

Sponsors & Collaborators

  • Shanghai Yueyang Integrated Medicine Hospital

    lead OTHER

Principal Investigators

  • Yan Han, Ph.D. · Shanghai University of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-11-01
Completion
2023-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05663307 on ClinicalTrials.gov